The Journal of Contemporary Dental Practice

Register      Login



Volume / Issue

Online First

Related articles

VOLUME 17 , ISSUE 12 ( December, 2016 ) > List of Articles


Rebamipide to Manage Stomatopyrosis in Oral Submucous Fibrosis

Joanna Baptist, Shrijana Shakya

Citation Information : Baptist J, Shakya S. Rebamipide to Manage Stomatopyrosis in Oral Submucous Fibrosis. J Contemp Dent Pract 2016; 17 (12):1009-1012.

DOI: 10.5005/jp-journals-10024-1972

Published Online: 01-04-2017

Copyright Statement:  Copyright © 2016; The Author(s).



Oral submucous fibrosis (OSF) causes progressive debilitating symptoms, such as oral burning sensation (stomatopyrosis) and limited mouth opening. The standard of care (SOC) protocol includes habit cessation, intralesional steroid and hyaluronidase injections, and mouth opening exercises. The objective of the study was to evaluate efficacy of rebamipide in alleviating burning sensation of the oral mucosa in OSF in comparison with SOC intralesional steroid injections.

Materials and methods

Twenty OSF patients were divided into two groups [rebamipide (100 mg TID for 21 days) and betamethasone (4 mg/mL biweekly for 4 weeks)] of 10 each by random sampling. Burning sensation was assessed every week for 1 month. Burning sensation scores were analyzed using repeated measures analysis of variance (ANOVA) and paired t-test.


Change in burning sensation score was significant (p < 0.05) in the first four visits. However, score between the 4th and 5th visit was not statistically significant (p > 0.05).


Our study has shown that rebamipide can be considered as an effective modality to manage burning sensation in patients suffering from OSF.

Clinical significance

Considering stomatopyrosis and trismus as a major cause for inability to eat in OSF, use of newer adjunctive modalities, such as rebamipide will ease patients suffering and also encourage them to consume food.

How to cite this article

Baptist J, Shakya S, Ongole R. Rebamipide to Manage Stomatopyrosis in Oral Submucous Fibrosis. J Contemp Dent Pract 2016;17(12):1009-1012.

PDF Share
  1. Better grade of tumor differentiation of oral squamous cell carcinoma arising in background of oral submucous fibrosis. Med Hypotheses 2013 Oct;81(4):540-543.
  2. HLA typing in Taiwanese patients with oral sub mucous fibrosis. J Oral Pathol Med 2004 Apr;33(4):191-199.
  3. Benign and malignant tumors of the oral cavity. In:Shafer, WG; Hine, MK; Levy, BM, editors, A textbook of oral pathology. 4th ed. Philadelphia, PA: WB Saunders; 1983. p. 86-229.
  4. Regional office for South-East Asia global adult tobacco survey (GATS): India country report. New Delhi: WHO-SEARO; 2009 [cited 2014 Mar 25]. Available from:
  5. Toxicity of gutkha, a smokeless tobacco product gone global: is there more to the toxicity than nicotine? Int J Environ Res Public Health 2014 Jan;11(1):919-933.
  6. Reactive oxygen species are crucial for hydroxychavicol toxicity toward KB epithelial cells. Cell Mol Life Sci 2004 Jan;61(1):83-96.
  7. Role of oxidative stress and antioxidants in aetiopathogenesis and management of oral submucous fibrosis. Indian J Clin Biochem 2004 Jan;19(1):138-141.
  8. Inhibition of lipid peroxidation, NF-kB activation and IL-8 production by rebamipide in Helicobacter pylori-stimulated gastric epithelial cells. Dig Dis Sci 2000 Mar;45(3):621-628.
  9. Clinical evaluation of different treatment methods for oral submucous fibrosis. A 10-year experience with 150 cases. J Oral Pathol Med 1995 Oct;24(9):402-406.
  10. Pentoxifylline therapy: a new adjunct in the treatment of oral submucous fibrosis. Indian J Dent Res 2006 Oct-Dec;17(4):190-198.
  11. Efficacy of lycopene in the management of oral submucous fibrosis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007 Feb;103(2):207-213.
  12. Treatment of oral submucous fibrosis by collagenase: effects on oral opening and eating function. Oral Dis 2007 Aug;13(4):407-413.
  13. Oral submucous fibrosis-treatment with hyalase. J Laryngol Otol 1985 Jan;99(1):57-59.
  14. Characteristics of attenuating effects of rebamipide, an anti-ulcer agent, on oxidative bursts of human neutrophils. J Pharmacol Sci 2003 Feb;91(2):153-157.
  15. Rebamipide, a cytoprotective drug, increases gastric mucus secretion in human: evaluations with endoscopic gastrin test. Dig Dis Sci 2009 Jul;54(7):1500-1507.
  16. Transcriptome analysis for cytoprotective actions of rebamipide against indomethacin- nduced gastric mucosal injury in rats. J Clin Biochem Nutr 2007 Nov;41(3):202-210.
  17. Efficacy of rebamipide as adjunctive therapy in the treatment of recurrent oral aphthous ulcers in patients with Behçet's disease: a randomised, double-blind, placebo-controlled study. Drug R D 2003;4(1):19-28.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.